|
|
|
|
LEADER |
05031nma a2201249 u 4500 |
001 |
EB002143816 |
003 |
EBX01000000000000001281942 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
230202 ||| eng |
020 |
|
|
|a 9783036555188
|
020 |
|
|
|a 9783036555171
|
020 |
|
|
|a books978-3-0365-5518-8
|
100 |
1 |
|
|a Manini, Claudia
|
245 |
0 |
0 |
|a Clear Cell Renal Cell Carcinoma 2021-2022
|h Elektronische Ressource
|
260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2022
|
300 |
|
|
|a 1 electronic resource (342 p.)
|
653 |
|
|
|a machine learning
|
653 |
|
|
|a prediction model
|
653 |
|
|
|a pathway analysis
|
653 |
|
|
|a radiomics
|
653 |
|
|
|a sunitinib
|
653 |
|
|
|a resistance
|
653 |
|
|
|a transcriptome
|
653 |
|
|
|a nivolumab
|
653 |
|
|
|a responsiveness
|
653 |
|
|
|a T-cells
|
653 |
|
|
|a prognostic factor
|
653 |
|
|
|a angiogenesis
|
653 |
|
|
|a hypoxia
|
653 |
|
|
|a renal cancer
|
653 |
|
|
|a inter-tumoral heterogeneity
|
653 |
|
|
|a architectural patterns
|
653 |
|
|
|a n/a
|
653 |
|
|
|a tumor microenvironment
|
653 |
|
|
|a translational
|
653 |
|
|
|a tissue slice culture
|
653 |
|
|
|a diagnosis
|
653 |
|
|
|a first-line treatment
|
653 |
|
|
|a disease progression
|
653 |
|
|
|a PD1
|
653 |
|
|
|a magnetic resonance
|
653 |
|
|
|a tyrosine kinase inhibitors
|
653 |
|
|
|a clear cell kidney cancer
|
653 |
|
|
|a prognostic factors
|
653 |
|
|
|a epigenetics
|
653 |
|
|
|a metastatic clear cell renal cell carcinoma
|
653 |
|
|
|a combinations
|
653 |
|
|
|a clear-cell renal cell carcinoma
|
653 |
|
|
|a imaging
|
653 |
|
|
|a plasma
|
653 |
|
|
|a thyroid
|
653 |
|
|
|a intra-tumoral heterogeneity
|
653 |
|
|
|a immunotherapy
|
653 |
|
|
|a molecular features
|
653 |
|
|
|a inter-metastatic heterogeneity
|
653 |
|
|
|a immune related adverse events (irAEs)
|
653 |
|
|
|a PBRM1
|
653 |
|
|
|a single-cell RNA sequencing
|
653 |
|
|
|a ddPCR
|
653 |
|
|
|a PD-L1
|
653 |
|
|
|a cancer immunotherapy
|
653 |
|
|
|a treatment resistance
|
653 |
|
|
|a renal cell cancer
|
653 |
|
|
|a adjuvant therapy
|
653 |
|
|
|a clear cell renal cell carcinoma
|
653 |
|
|
|a intratumor heterogeneity
|
653 |
|
|
|a DNA methylation
|
653 |
|
|
|a circulating miRNA
|
653 |
|
|
|a biomarkers
|
653 |
|
|
|a immune landscape
|
653 |
|
|
|a cystic tumor
|
653 |
|
|
|a oleic acid
|
653 |
|
|
|a immune checkpoint inhibitors
|
653 |
|
|
|a prognosis
|
653 |
|
|
|a multisite tumor sampling
|
653 |
|
|
|a biomarker
|
653 |
|
|
|a kidney
|
653 |
|
|
|a immune checkpoint inhibitor
|
653 |
|
|
|a SCD-1
|
653 |
|
|
|a renal cell carcinoma
|
653 |
|
|
|a malignancy
|
653 |
|
|
|a PD-1
|
653 |
|
|
|a surgery
|
653 |
|
|
|a RNA sequencing
|
653 |
|
|
|a miRNA
|
653 |
|
|
|a endothelial cells
|
653 |
|
|
|a gene expression
|
653 |
|
|
|a Clinical and internal medicine / bicssc
|
653 |
|
|
|a Medicine and Nursing / bicssc
|
653 |
|
|
|a immunohistochemistry
|
653 |
|
|
|a cutaneous
|
653 |
|
|
|a histomorphological features
|
653 |
|
|
|a radiogenomics
|
700 |
1 |
|
|a López, José I.
|
700 |
1 |
|
|a Manini, Claudia
|
700 |
1 |
|
|a López, José I.
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
028 |
5 |
0 |
|a 10.3390/books978-3-0365-5518-8
|
856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/6216
|7 0
|x Verlag
|3 Volltext
|
856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/93788
|z DOAB: description of the publication
|
082 |
0 |
|
|a 363
|
082 |
0 |
|
|a 610
|
082 |
0 |
|
|a 540
|
520 |
|
|
|a Clear cell renal cell carcinoma is currently one of the most interesting areas of study in oncology. Despite the advances made in this field, this tumor continues to be a health problem of major concern in Western societies, seriously affecting public health services. Several characteristics of this tumor make it an exciting meeting point for translational collaboration between clinicians and basic researchers. Clear cell renal cell carcinoma is a paradigmatic example of inter- and intra-tumor heterogeneity from morphological, immunohistochemical, and molecular viewpoints. This tumor is also a good example to investigate the complexity of tumor/tumor and tumor/environment relationships from an ecological perspective. A deeper identification of the varied internal tumor self-organization through the specialization of cell clones and subclones as local invaders and metastasizers, on one hand, and the interactions of specific subsets of tumor cells with the local host microenvironment, on the other, will significantly enrich our knowledge of this neoplasm. Clear cell renal cell carcinoma is also a paradigmatic test bench for antiangiogenic and immune checkpoint blockage therapies. The refinement of these therapeutic tools administered alone or in combination is a hot issue in oncology, and several international trials are underway.
|